查看购物车
  • Traditional Chinese
  • English
  • Japanese
拉丁美洲 NGS 市场（按产品、技术、应用和最终用户划分）- 分析和预测（2024-2034 年）
市场调查报告书
商品编码
1654124

拉丁美洲 NGS 市场（按产品、技术、应用和最终用户划分）- 分析和预测（2024-2034 年）

Latin America NGS Market: Focus on Offering, Technology, Application, and End User - Analysis and Forecast, 2024-2034
出版日期: | 出版商: BIS Research | 英文 169 Pages | 商品交期: 1-5个工作天内

价格

预计2024年拉丁美洲NGS市场规模将达2.6804亿美元。

预计到 2034 年，市场规模将达到 5.972 亿美元，2024-2034 年预测期间的复合年增长率为 8.34%。肿瘤学、感染疾病研究和产前诊断领域中日益增多的应用推动了对NGS的需求。

主要市场统计数据
预测期 2024-2034
2024 年评估 2.6804亿美元
2034 年预测 5.972亿美元
复合年增长率 8.34%

次世代定序(NGS) 已经改变了癌症诊断，可以同时分析多个基因，促进对肿瘤的准确分析，识别可操作的突变，并根据标靶治疗定制治疗计划。 NGS 是一种非侵入性技术，广泛用于液态切片，透过分析血液中的循环肿瘤 DNA（ctDNA）来帮助追踪癌症进展。此外，肿瘤学的转化研究在很大程度上依赖NGS来探讨肿瘤遗传学，从而能够识别导致癌症进展或治疗抗药性的基因改变。这推动了新药和标靶治疗的发展。

除了肿瘤学之外，NGS还应用于非侵入性产前检测（NIPT），透过分析胎儿DNA来检测唐氏症等染色体异常。群体基因组学涉及大规模群体定序，可以研究遗传多样性、基因-环境交互作用和疾病感受性。这些进步为个人化医疗铺平了道路，个人化医疗可根据人群独特的基因特征制定治疗方案。

NGS在病原体检测中也扮演重要角色。整个基因组定序有助于对感染疾病，特别是抗药性病原体的基因组监测。 NGS 正在加速我们对病毒、细菌和真菌基因组成的了解，有助于疫苗开发和抗病毒治疗。这种能力对于管理疾病爆发至关重要，包括在新冠肺炎大流行期间。

拉丁美洲采用 NGS 技术的原因是癌症、慢性病和罕见遗传疾病的发生率不断上升。巴西和墨西哥等国家正在投资基因组检测和肿瘤学，将基于NGS的诊断整合到癌症治疗中。随着基因组资料变得更加容易取得和便宜，这一趋势预计将持续下去，促进个人化医疗的发展。

本报告研究了拉丁美洲的NGS市场，并提供了市场的概述，主要趋势按产品、技术、应用和最终用户细分，以及市场参与者的概况。

目录

执行摘要

研究范围

第一章 市场概况

  • 产品定义
  • 纳入与排除标准
  • 拉丁美洲 NGS 市场规模，百万美元，2023-2034 年
  • NGS 的监管格局
  • 市场动态
  • 2023 年至 2033 年 NGS 检测量分析（依适应症）
  • 2023 年至 2033 年各国基于 NGS 的检测量分析
  • 拉丁美洲NGS市场测试情景

第2章 奉献

  • 成长占有率矩阵
    • 装置
    • 套件和耗材
    • 软体
    • 服务

第 3 章 依技术

  • 成长占有率矩阵
    • Ion Torrent 半导体定序
    • 可逆终止序列
    • 单分子即时定序
    • 奈米孔定序技术
    • 其他的

第 4 章 按用途

  • 成长占有率矩阵
    • 临床
    • 转化研究

第 5 章：按最终用户

  • 成长占有率矩阵
    • 医院和诊所
    • 学术研究所
    • 製药和生物技术公司
    • 政府研究所
    • 其他的

第六章 按国家

  • 概述
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 哥斯大黎加
    • 波多黎各
    • 其他的

第七章 竞争基准化分析与公司简介

  • 2023 年拉丁美洲 NGS市场占有率（按公司划分）
  • 竞争性基准化分析
    • 重点发展分析
  • 2023 年各国 NGS 仪器安装量
  • 公司简介
    • Illumina Inc.
    • Thermo Fisher Scientific Inc.
    • QIAGEN NV
    • PacBio
    • Agilent Technologies, Inc.
    • Oxford Nanopore Technologies plc
    • Danaher Corporation
    • F. Hoffmann-La Roche Ltd
    • Revvity, Inc.
    • MGI Tech Co., Ltd.
Product Code: BHL2510SA

Market Overview

The Latin America NGS market was valued at $268.04 million in 2024 and is anticipated to reach $597.20 million by 2034, witnessing a CAGR of 8.34% during the forecast period 2024-2034. The demand for NGS is driven by increasing applications in oncology, infectious disease research, and prenatal diagnostics.

Market Introduction

KEY MARKET STATISTICS
Forecast Period2024 - 2034
2024 Evaluation$268.04 Million
2034 Forecast$597.20 Million
CAGR8.34%

Next-generation sequencing (NGS) has transformed cancer diagnostics by enabling simultaneous analysis of multiple genes, facilitating precise tumor profiling, identifying actionable mutations, and customizing treatment plans through targeted therapies. NGS is extensively used in liquid biopsies, which are non-invasive and aid in tracking cancer progression by analyzing circulating tumor DNA (ctDNA) in the bloodstream. Moreover, translational research in oncology heavily relies on NGS to study tumor genetics, enabling the identification of genetic alterations driving cancer progression and resistance to therapies. This has propelled the development of new drugs and targeted treatments.

Beyond oncology, NGS is applied in non-invasive prenatal testing (NIPT) to detect chromosomal abnormalities, such as Down syndrome, by analyzing fetal DNA. Population genomics, involving large-scale sequencing of populations, has enabled studies on genetic diversity, gene-environment interactions, and disease susceptibility. These advancements pave the way for personalized medicine, tailoring treatments to population-specific genetic profiles.

NGS also plays a crucial role in pathogen detection. It sequences entire genomes, aiding in genomic surveillance of infectious diseases, particularly drug-resistant pathogens. NGS facilitates understanding of the genetic makeup of viruses, bacteria, and fungi, contributing to vaccine development and antiviral therapies. This capability has been critical in managing disease outbreaks, including during the COVID-19 pandemic.

The adoption of NGS technologies in Latin America has been fueled by the rising prevalence of cancer, chronic diseases, and rare genetic disorders. Countries like Brazil and Mexico are investing in genomic testing and oncology, integrating NGS-based diagnostics for cancer treatment. These trends are expected to continue as genomic data becomes more accessible and affordable, fostering the growth of personalized medicine.

Impact of COVID-19

The pandemic underscored the importance of genomic surveillance, accelerating investments in NGS infrastructure. Latin American countries utilized NGS for monitoring viral mutations and understanding the epidemiology of COVID-19. This has set the stage for enhanced genomic capabilities to manage future infectious disease threats.

Supply Chain Disruptions:

  • Manufacturing and transportation challenges temporarily affected the availability of NGS instruments and consumables.

Shift to Remote Workflows:

  • Increased adoption of cloud-based genomic platforms allowed continuity of research during lockdowns.

Market Segmentation:

Segmentation 1: by Offering

  • Services
    • The largest segment, contributing 38.50% to the market in 2023, projected to grow to 40.55% by 2034.
  • Kits and Consumables
    • Accounted for 34.41% of the market in 2023, expected to retain significant share due to consistent demand for consumables in NGS workflows.
  • Software
    • Held 8.68% in 2023, crucial for managing and analyzing large genomic datasets.
  • Instruments
    • Represented 18.42% of the market in 2023, with growth driven by technological advancements.

Segmentation 2: by Technology

  • Reversible Terminator Sequencing
    • Dominates the market with a 77.80% share in 2023, projected to grow to 83.09% by 2034 due to its efficiency and cost-effectiveness.
  • Ion Torrent Semiconductor Sequencing
    • Accounted for 8.65% in 2023, used for small-scale sequencing projects.
  • Single Molecule Real-Time Sequencing
  • Nanopore Sequencing Technology
  • Other Technology

Segmentation 3: by Application

  • Clinical
    • Largest segment, with 52.43% in 2023, expected to grow to 56.50% by 2034. Key applications include cancer diagnostics, prenatal testing, and infectious disease management.
  • Translational Research
    • Accounted for 47.57% in 2023, pivotal for drug discovery and understanding disease mechanisms.

Segmentation 4: by End-User

  • Academic and Research Institutes
    • Largest share in 2023 (39.06%), projected to grow to 39.51% by 2034. Growth driven by increased research activities.
  • Hospitals and Clinics
    • Accounted for 26.90% in 2023, with adoption driven by expanding clinical applications.
  • Pharmaceutical and Biotechnology Companies
    • Represented 19.00% in 2023, leveraging NGS for drug development and biomarker discovery.
  • Government Laboratories
  • Other End User

Segmentation 5: by Country

  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
  • Costa Rica
  • Puerto Rico
  • Rest-of-Latin America

On the basis of country, Brazil segment accounted for the largest share in 2023, holding a 48.35% market share. Mexico is expected to grow at a fastest rate of 10.41% over a forecast period.

Demand - Drivers and Limitations

The following are the demand drivers for Latin America NGS market:

  • Rising Demand for NGS Driven by Growing Disease Burden
  • Expanding Localized Genomics Infrastructure and Partnerships

The market is expected to face some limitations due to the following challenges:

  • Lack of Funding and Reimbursement
  • Lack of Education, Awareness, and Specialists

Future Outlook

The Latin America NGS market is poised for significant growth, driven by advancements in sequencing technologies, government investments, and increasing clinical applications. The integration of AI, expansion of population genomics initiatives, and focus on personalized medicine will be pivotal in shaping the market's trajectory. As NGS becomes more accessible, its role in improving healthcare outcomes across the region will continue to expand.

How can this report add value to an organization?

Product/Innovation Strategy: The Latin America NGS market has been extensively segmented on the basis of various categories, such as offering, technology, application, and end-user. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: A detailed competitive benchmarking of the players operating in the Latin America NGS market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.

Key Companies Profiled:

  • Illumina Inc.
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • PacBio
  • Agilent Technologies, Inc.
  • Oxford Nanopore Technologies plc
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Revvity, Inc.
  • MGI Tech Co., Ltd.

Table of Contents

Executive Summary

Research Methodology

Scope of the Study

1 Market Overview

  • 1.1 Product Definition
  • 1.2 Inclusion and Exclusion Criteria
  • 1.3 Latin America NGS Market Size, $ Million, 2023-2034
  • 1.4 Regulatory Landscape for NGS
    • 1.4.1 Regulatory Landscape for Latin America
    • 1.4.2 Regulatory Landscape for Brazil
    • 1.4.3 Regulatory Landscape for Mexico
    • 1.4.4 Regulatory Landscape for Colombia
    • 1.4.5 Regulatory Landscape for Argentina
    • 1.4.6 Regulatory Landscape for Chile
    • 1.4.7 Regulatory Landscape for Costa Rica
    • 1.4.8 Regulatory Landscape for Puerto Rico
  • 1.5 Market Dynamics
    • 1.5.1 Market Drivers
      • 1.5.1.1 Rising Demand for NGS Driven by Growing Disease Burden
      • 1.5.1.2 Expanding Localized Genomics Infrastructure and Partnerships
    • 1.5.2 Market Restraints
      • 1.5.2.1 Cost Effectiveness
      • 1.5.2.2 Lack of Funding and Reimbursement
      • 1.5.2.3 Lack of Education, Awareness, and Specialists
    • 1.5.3 Market Trends
    • 1.5.4 Future Opportunities
      • 1.5.4.1 Establishing Diagnostic Centers
      • 1.5.4.2 Expanding Genomic Data for Advanced NGS Solutions
  • 1.6 NGS-Based Testing Volume Analysis (by Indication), 2023-2033
    • 1.6.1 Oncology
    • 1.6.2 Rare and Hereditary Diseases
    • 1.6.3 Reproductive Health
    • 1.6.4 Direct-to-Consumer
    • 1.6.5 Infectious Disease Testing
    • 1.6.6 Others
  • 1.7 NGS-Based Testing Volume Analysis (By Country), 2023-2033
    • 1.7.1 Brazil
    • 1.7.2 Mexico
    • 1.7.3 Argentina
    • 1.7.4 Colombia
    • 1.7.5 Rest-of-LATAM
  • 1.8 LATAM NGS Market Testing Scenario
    • 1.8.1 Local (Latin America) Vs Outsourced Testing Scenario
    • 1.8.2 NGS-Based Testing Scenario, Outsourced Test Type (by Indication)
    • 1.8.3 NGS-Based Testing Scenario, Local Vs Outsourced Test Type (by Country)
      • 1.8.3.1 NGS-Based Testing Scenario, Outsourced Test Type, (by Country)
      • 1.8.3.2 NGS-Based Testing Scenario, Local Test Type, (by Country)

2 Offering

  • 2.1 Growth-Share Matrix
    • 2.1.1 Instruments
      • 2.1.1.1 Integrated Workflow Instruments
      • 2.1.1.2 Sequencing Instruments
      • 2.1.1.3 Library Preparation Instruments
    • 2.1.2 Kits and Consumables
      • 2.1.2.1 Library Preparation Kits
      • 2.1.2.2 Target Enrichment Kits
      • 2.1.2.3 Sequencing Kits
      • 2.1.2.4 Multiuse Kits
    • 2.1.3 Software
    • 2.1.4 Services

3 Technology

  • 3.1 Growth-Share Matrix
    • 3.1.1 Ion Torrent Semiconductor Sequencing
    • 3.1.2 Reversible Terminator Sequencing
    • 3.1.3 Single Molecule Real-Time Sequencing
    • 3.1.4 Nanopore Sequencing Technology
    • 3.1.5 Other Technology

4 Application

  • 4.1 Growth-Share Matrix
    • 4.1.1 Clinical
      • 4.1.1.1 Oncology
        • 4.1.1.1.1 Haematological Malignancy
        • 4.1.1.1.2 Solid Tumor
      • 4.1.1.2 Neurological Disease Testing
      • 4.1.1.3 Reproductive Health Testing
      • 4.1.1.4 Rare Disease Diagnostics
      • 4.1.1.5 Infectious Disease Testing
      • 4.1.1.6 Others
    • 4.1.2 Translational Research

5 End-User

  • 5.1 Growth-Share Matrix
    • 5.1.1 Hospitals and Clinics
    • 5.1.2 Academic and Research Institutes
    • 5.1.3 Pharmaceutical and Biotechnology Companies
    • 5.1.4 Government Laboratories
    • 5.1.5 Other End User

6 Country

  • 6.1 Overview
    • 6.1.1 Brazil
      • 6.1.1.1 Current Pharma Programs for Biomarker NGS Tests/Target Therapy Selection
      • 6.1.1.2 Brazil NGS Test Reimbursement Scenario/Insurance Coverage
    • 6.1.2 Mexico
      • 6.1.2.1 Current Pharma Programs for Biomarker NGS Tests/Target Therapy Selection
      • 6.1.2.2 Mexico NGS Test Reimbursement Scenario/Insurance Coverage
    • 6.1.3 Argentina
      • 6.1.3.1 Current Pharma Programs for Biomarker NGS Tests/Target Therapy Selection
      • 6.1.3.2 Argentina NGS Test Reimbursement Scenario/Insurance Coverage
    • 6.1.4 Colombia
      • 6.1.4.1 Current Pharma Programs for Biomarker NGS Tests/Target Therapy Selection
      • 6.1.4.2 Columbia NGS Test Reimbursement Scenario/Insurance Coverage
    • 6.1.5 Chile
      • 6.1.5.1 Current Pharma Programs for Biomarker NGS Tests/Target Therapy Selection
      • 6.1.5.2 Chile NGS Test Reimbursement Scenario/Insurance Coverage
    • 6.1.6 Costa Rica
      • 6.1.6.1 Current Pharma Programs for Biomarker NGS Tests/Target Therapy Selection
      • 6.1.6.2 Costa Rica NGS Test Reimbursement Scenario/Insurance Coverage
    • 6.1.7 Puerto Rico
      • 6.1.7.1 Current Pharma Programs for Biomarker NGS Tests/Target Therapy Selection
      • 6.1.7.2 Puerto Rico NGS Test Reimbursement Scenario/Insurance Coverage
    • 6.1.8 Rest-of-Latin America
      • 6.1.8.1 Current Pharma Programs for Biomarker NGS Tests/Target Therapy Selection
      • 6.1.8.2 Rest-of-Latin America NGS Test Reimbursement Scenario/Insurance Coverage

7 Competitive Benchmarking and Company Profiles

  • 7.1 Latin America NGS Market Share by Company, 2023
    • 7.1.1 Company Market Share
    • 7.1.2 Key Takeaways
  • 7.2 Competitive Benchmarking
    • 7.2.1 Key Development Analysis
      • 7.2.1.1 Product Launch and Regulatory Approvals
      • 7.2.1.2 Merger and Acquisition
      • 7.2.1.3 Business Expansion
      • 7.2.1.4 Product Upgradation
      • 7.2.1.5 Partnership, Collaboration, and Agreement
  • 7.3 Installed Base of NGS Instruments by Country, 2023
  • 7.4 Company Profiles
    • 7.4.1 Illumina Inc.
      • 7.4.1.1 Company Overview
      • 7.4.1.2 Role of Illumina in the Latin America NGS Market
      • 7.4.1.3 Customer Group and Key Competitors
      • 7.4.1.4 Analyst Perception
    • 7.4.2 Thermo Fisher Scientific Inc.
      • 7.4.2.1 Company Overview
      • 7.4.2.2 Role of Thermo Fisher Scientific Inc. in the Latin America NGS Market
      • 7.4.2.3 Customer Group and Key Competitors
      • 7.4.2.4 Analyst Perception
    • 7.4.3 QIAGEN N.V.
      • 7.4.3.1 Company Overview
      • 7.4.3.2 Role of QIAGEN N.V. in the Latin America NGS Market
      • 7.4.3.3 Customer Group and Key Competitors
      • 7.4.3.4 Analyst Perception
    • 7.4.4 PacBio
      • 7.4.4.1 Company Overview
      • 7.4.4.2 Role of PacBio in the Latin America NGS Market
      • 7.4.4.3 Customer Group and Key Competitors
      • 7.4.4.4 Analyst Perception
    • 7.4.5 Agilent Technologies, Inc.
      • 7.4.5.1 Company Overview
      • 7.4.5.2 Role of Agilent Technologies Inc. in the Latin America NGS Market
      • 7.4.5.3 Customer Group and Key Competitors
      • 7.4.5.4 Analyst Perception
    • 7.4.6 Oxford Nanopore Technologies plc
      • 7.4.6.1 Company Overview
      • 7.4.6.2 Role of Oxford Nanopore Technologies plc in the Latin America NGS Market
      • 7.4.6.3 Customer Group and Key Competitors
      • 7.4.6.4 Analyst Perception
    • 7.4.7 Danaher Corporation
      • 7.4.7.1 Company Overview
      • 7.4.7.2 Role of Danaher Corporation in the Latin America NGS Market
      • 7.4.7.3 Customer Group and Key Competitors
      • 7.4.7.4 Analyst Perception
    • 7.4.8 F. Hoffmann-La Roche Ltd
      • 7.4.8.1 Company Overview
      • 7.4.8.2 Role of F. Hoffmann-La Roche Ltd. in the Latin America NGS Market
      • 7.4.8.3 Customer Group and Key Competitors
      • 7.4.8.4 Analyst Perception
    • 7.4.9 Revvity, Inc.
      • 7.4.9.1 Company Overview
      • 7.4.9.2 Role of Revvity, Inc. in the Latin America NGS Market
      • 7.4.9.3 Customer Group and Key Competitors
      • 7.4.9.4 Analyst Perception
    • 7.4.10 MGI Tech Co., Ltd.
      • 7.4.10.1 Company Overview
      • 7.4.10.2 Role of MGI Tech Co. Ltd in the Latin America NGS Market
      • 7.4.10.3 Customer Group and Key Competitors
      • 7.4.10.4 Analyst Perception

List of Figures

  • Figure 1: Latin America NGS Market, $Million, 2023-2034
  • Figure 2: Latin America NGS Market (by Offering), (%), 2023 Vs. 2034
  • Figure 3: Latin America NGS Market (by Technology), (%), 2023 Vs. 2034
  • Figure 4: Latin America NGS Market (by Application), (%), 2023 Vs. 2034
  • Figure 5: Latin America NGS Market (by End User), (%), 2023 Vs. 2034
  • Figure 6: Latin America NGS Market (by Country), (%), 2023 Vs. 2034
  • Figure 7: Latin America NGS Market Research Methodology
  • Figure 8: Latin America NGS Market: Segmentation
  • Figure 9: Latin America NGS Market Size and, $Million, 2023-2034
  • Figure 10: Incidence of Cancer in Key Countries of Latin America in 2022, 2025, 2030, and 2040
  • Figure 11: Comparison between the Average Cost of NGS Test in Latin America and the Average Monthly Salary of People in Brazil, Mexico, and Argentina, $
  • Figure 12: Latin America NGS Market, Testing Volume (by Indication), (in Thousands), 2023-2033
  • Figure 13: Latin America NGS Market, Testing Volume, by Indication (Oncology), (in Thousands), 2023-2033
  • Figure 14: Latin America NGS Market, Testing Volume, by Indication (Rare and Hereditary Disease), (in Thousands), 2023-2033
  • Figure 15: Latin America NGS Market, Testing Volume, by Indication (Reproductive Health), (in Thousands), 2023-2033
  • Figure 16: Latin America NGS Market, Testing Volume, by Indication (Direct to Consumer), (in Thousands), 2023-2033
  • Figure 17: Latin America NGS Market, Testing Volume, by Indication (Infectious Disease), (in Thousands), 2023-2033
  • Figure 18: Latin America NGS Market, Testing Volume, by Indication (Others), (in Thousands), 2023-2033
  • Figure 19: Latin America NGS Market, Testing Volume (by Country), (in Thousands), 2023-2033
  • Figure 20: Latin America NGS Market, Testing Volume, by Country (Brazil), (in Thousands), 2023-2033
  • Figure 21: Latin America NGS Market, Testing Volume, by Country (Mexico), (in Thousands), 2023-2033
  • Figure 22: Latin America NGS Market, Testing Volume, by Country (Argentina), (in Thousands), 2023-2033
  • Figure 23: Latin America NGS Market, Testing Volume, by Country (Colombia), (in Thousands), 2023-2033
  • Figure 24: Latin America NGS Market, Testing Volume, by Country (Rest-of-LATAM), (in Thousands), 2023-2033
  • Figure 25: Latin America NGS Testing Scenario, Volume of Test (Local vs. Outsourced), (in Thousands)2023-2033
  • Figure 26: Latin America NGS Testing Scenario, Volume of Test (Outsourced Test Type by Indication), (in Thousands) 2023-2033
  • Figure 27: Latin America NGS Testing Scenario, Volume of Test (Outsourced Test Type by Country), (in Thousands) 2023-2033
  • Figure 28: Latin America NGS Testing Scenario, Volume of Test (Local Test Type by Country), (in Thousands) 2023-2033
  • Figure 29: Latin America NGS Market (Instrument), $Million, 2023-2034
  • Figure 30: Latin America NGS Market (by Instrument) (Integrated Workflow Instruments), $Million, 2023-2034
  • Figure 31: Latin America NGS Market (by Instrument) (Sequencing Instruments), $Million, 2023-2034
  • Figure 32: Latin America NGS Market (by Instrument) (Library Preparation Instruments), $Million, 2023-2034
  • Figure 33: Latin America NGS Market (Kits and Consumables), $Million, 2023-2034
  • Figure 34: Latin America NGS Market (by Kits and Consumables) (Library Preparation Kits), $Million, 2023-2034
  • Figure 35: Latin America NGS Market (by Kits and Consumables) (Target Enrichment Kits), $Million, 2023-2034
  • Figure 36: Latin America NGS Market (by Kits and Consumables) (Sequencing Kits), $Million, 2023-2034
  • Figure 37: Latin America NGS Market (by Kits and Consumables) (Multiuse Kits) $Million, 2023-2034
  • Figure 38: Latin America NGS Market (Software), $Million, 2023-2034
  • Figure 39: Latin America NGS Market (Services), $Million, 2023-2034
  • Figure 40: Latin America NGS Market (Ion Torrent Semiconductor Sequencing), $Million, 2023-2034
  • Figure 41: Latin America NGS Market (Reversible Terminator Sequencing), $Million, 2023-2034
  • Figure 42: Latin America NGS Market (Single Molecule Real-Time Sequencing) $Million, 2023-2034
  • Figure 43: Latin America NGS Market (Nanopore Sequencing Technology), $Million, 2023-2034
  • Figure 44: Latin America NGS Market (Other Technology), $Million, 2023-2034
  • Figure 45: Latin America NGS Market (Clinical), $Million, 2023-2034
  • Figure 46: Latin America NGS Market (Oncology), $Million, 2023-2034
  • Figure 47: Latin America Oncology Market (Haematological Malignancy), $Million, 2023-2034
  • Figure 48: Latin America Oncology Market (Solid Tumor), $Million, 2023-2034
  • Figure 49: Latin America NGS Market (Neurological Disease Testing), $Million, 2023-2034
  • Figure 50: Latin America NGS Market (Reproductive Health Testing), $Million, 2023-2034
  • Figure 51: Latin America NGS Market (Rare Disease Diagnostics), $Million, 2023-2034
  • Figure 52: Latin America NGS Market (Infectious Disease Testing), $Million, 2023-2034
  • Figure 53: Latin America NGS Market (Others), $Million, 2023-2034
  • Figure 54: Latin America NGS Market (Translational Research), $Million, 2023-2034
  • Figure 55: Latin America NGS Market (Hospitals and Clinics), $Million, 2023-2034
  • Figure 56: Latin America NGS Market (Academic and Research Institutes), $Million, 2023-2034
  • Figure 57: Latin America NGS Market (Pharmaceutical and Biotechnology Companies), $Million, 2023-2034
  • Figure 58: Latin America NGS Market (Government Laboratories), $Million, 2023-2034
  • Figure 59: Latin America NGS Market (Other End User), $Million, 2023-2034
  • Figure 60: Latin America NGS Market (by Country), $Million, 2023-2034
  • Figure 61: Brazil NGS Market, $Million, 2023-2034
  • Figure 62: Brazil NGS Market, by Offering, $Million, 2023-2034
  • Figure 63: Brazil NGS Market, by Technology, $Million, 2023-2034
  • Figure 64: Brazil NGS Market, by Application, $Million, 2023-2034
  • Figure 65: Brazil NGS Market, by End User, $Million, 2023-2034
  • Figure 66: Mexico NGS Market, $Million, 2023-2034
  • Figure 67: Mexico NGS Market, by Offering, $Million, 2023-2034
  • Figure 68: Mexico NGS Market, by Technology, $Million, 2023-2034
  • Figure 69: Mexico NGS Market, by Application, $Million, 2023-2034
  • Figure 70: Mexico NGS Market, by End User, $Million, 2023-2034
  • Figure 71: Argentina NGS Market, $Million, 2023-2034
  • Figure 72: Argentina NGS Market, by Offering, $Million, 2023-2034
  • Figure 73: Argentina NGS Market, by Technology, $Million, 2023-2034
  • Figure 74: Argentina NGS Market, by Application, $Million, 2023-2034
  • Figure 75: Argentina NGS Market, by End User, $Million, 2023-2034
  • Figure 76: Colombia NGS Market, $Million, 2023-2034
  • Figure 77: Colombia NGS Market, by Offering, $Million, 2023-2034
  • Figure 78: Colombia NGS Market, by Technology, $Million, 2023-2034
  • Figure 79: Colombia NGS Market, by Application, $Million, 2023-2034
  • Figure 80: Colombia NGS Market, by End User, $Million, 2023-2034
  • Figure 81: Chile NGS Market, $Million, 2023-2034
  • Figure 82: Chile NGS Market, by Offering, $Million, 2023-2034
  • Figure 83: Chile NGS Market, by Technology, $Million, 2023-2034
  • Figure 84: Chile NGS Market, by Application, $Million, 2023-2034
  • Figure 85: Chile NGS Market, by End User, $Million, 2023-2034
  • Figure 86: Costa Rica NGS Market, $Million, 2023-2034
  • Figure 87: Costa Rica NGS Market, by Offering, $Million, 2023-2034
  • Figure 88: Costa Rica NGS Market, by Technology, $Million, 2023-2034
  • Figure 89: Costa Rica NGS Market, by Application, $Million, 2023-2034
  • Figure 90: Costa Rica NGS Market, by End User, $Million, 2023-2034
  • Figure 91: Puerto Rico NGS Market, $Million, 2023-2034
  • Figure 92: Puerto Rico NGS Market, by Offering, $Million, 2023-2034
  • Figure 93: Puerto Rico NGS Market, by Technology, $Million, 2023-2034
  • Figure 94: Puerto Rico NGS Market, by Application, $Million, 2023-2034
  • Figure 95: Puerto Rico NGS Market, by End User, $Million, 2023-2034
  • Figure 96: Rest-of-Latin America NGS Market, $Million, 2023-2034
  • Figure 97: Rest-of-Latin America NGS Market, by Offering, $Million, 2023-2034
  • Figure 98: Rest-of-Latin America NGS Market, by Technology, $Million, 2023-2034
  • Figure 99: Rest-of-Latin America NGS Market, by Application, $Million, 2023-2034
  • Figure 100: Rest-of-Latin America NGS Market, by End User, $Million, 2023-2034
  • Figure 101: Latin America NGS Market Share (by Company), 2023
  • Figure 102: Latin America NGS Market, Total Number of Key Developments, January 2020-September 2024
  • Figure 103: Latin America NGS Market, Total Number of Key Developments (by Company), January 2020-September 2024
  • Figure 104: New Offerings and Regulatory Approvals, January 2020-September 2024
  • Figure 105: Mergers and Acquisitions, January 2020-September 2024
  • Figure 106: Business Expansion, January 2020-September 2024
  • Figure 107: Product Upgradation, January 2020-September 2024
  • Figure 108: Partnership, Collaboration, and Agreement, January 2020-September 2024
  • Figure 109: Installed Base (by Country), 2023-2034

List of Tables

  • Table 1: Approval Timelines, License Validity, and Fees for Medical Devices
  • Table 2: Medical Device Classification System
  • Table 3: Medical Device Classification System
  • Table 4: Additional Information Regarding Approvals
  • Table 5: Fee Structure
  • Table 6: Latin America Next-Generation Sequencing Market, Impact Analysis, 2023-2034
  • Table 7: Latin America NGS Market, Key Development Analysis, Company Wise